Patents by Inventor Tim Owens
Tim Owens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220112724Abstract: An attachment system for attaching architectural facade panels to a wall, the attachment system having an elongated base rail, a Z-adjustment clip, an X-Y adjustment clip, and architectural panel. The base rail is configured to fasten to the wall. The Z-adjustment clip is configured to couple to the base rail. One or both of the fastening holes of the base rail or the fastening hole of the Z-adjustment clip are slots. The X-Y adjustment clip is configured to couple to the Z-adjustment clip. One or both of the fastening hole of the Z-adjustment clip or the fastening holes of the X-Y adjustment clip are slots. The architectural panel is configured to be secured to and supported by the X-Y adjustment clip. The slots allow for adjustment in each of the X, Y, and Z directions.Type: ApplicationFiled: October 8, 2021Publication date: April 14, 2022Inventors: Keith Chang, Steve Tatro, Tim Owen, Rich Meyer, Mark Golike, Darin Leonard, Chad Patterson
-
Publication number: 20220073522Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 19, 2021Publication date: March 10, 2022Applicant: Principia Biopharma Inc.Inventors: Tim Owens, Erik Verner
-
Patent number: 11040980Abstract: The present disclosure provides compounds of Formula (IA), such as, e.g., (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile having the chemical structure and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: GrantFiled: December 9, 2019Date of Patent: June 22, 2021Assignee: Principia Biopharma Inc.Inventors: Tim Owens, Erik Verner
-
Publication number: 20200190092Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 9, 2019Publication date: June 18, 2020Applicant: PRINCIPIA BIOPHARMA INC.Inventors: Tim OWENS, Erik VERNER
-
Patent number: 10533013Abstract: The present disclosure provides compounds of Formula (IA), such as, e.g., (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile having the chemical structure ?and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 11, 2018Date of Patent: January 14, 2020Assignee: Principia Biopharma Inc.Inventors: Tim Owens, Erik Verner
-
Publication number: 20180327413Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 11, 2018Publication date: November 15, 2018Applicant: PRINCIPIA BIOPHARMA INC.Inventors: Tim OWENS, Erik VERNER
-
Patent number: 9994576Abstract: The present disclosure provides compounds of Formula (II) as disclosed herein, and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: GrantFiled: January 15, 2016Date of Patent: June 12, 2018Assignee: PRINCIPIA BIOPHARMA INC.Inventors: Tim Owens, Erik Verner
-
Patent number: 9676778Abstract: The present disclosure provides compounds of formula (I) wherein the variables are as defined herein that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: GrantFiled: November 19, 2013Date of Patent: June 13, 2017Assignee: PRINCIPIA BIOPHARMA INC.Inventors: David Michael Goldstein, Kenneth Albert Brameld, Tim Owens
-
Publication number: 20160251358Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 15, 2016Publication date: September 1, 2016Applicant: PRINCIPIA BIOPHARMA INC.Inventors: Tim OWENS, Erik VERNER
-
Patent number: 9266895Abstract: The present disclosure provides compounds of Formula (IA) and or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 6, 2013Date of Patent: February 23, 2016Assignee: Principia Biopharma Inc.Inventors: Tim Owens, Erik Verner
-
Publication number: 20150291600Abstract: The present disclosure provides compounds that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: ApplicationFiled: November 19, 2013Publication date: October 15, 2015Inventors: David Michael Goldstein, Kenneth Albert Brameld, Tim Owens
-
Publication number: 20150094295Abstract: The present disclosure provides compounds of Formula (IA) and or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 6, 2013Publication date: April 2, 2015Inventors: Tim Owens, Erik Verner
-
Patent number: 8940744Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: GrantFiled: August 20, 2014Date of Patent: January 27, 2015Assignee: Principia Biopharma Inc.Inventors: Tim Owens, Erik Verner
-
Publication number: 20140364410Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 20, 2014Publication date: December 11, 2014Inventors: Tim OWENS, Erik VERNER
-
Publication number: 20080027856Abstract: A computer implemented method and system for displaying and calculating a vehicle loan can include input fields for adjusting parameters associated with the vehicle loan. The system can provide selectable gauges that can be used to adjust parameters of the vehicle loan. The gauges can comprise analog displays that include an indicator, such as a needle or graphical blocks. The indicator can be selected and repositioned. The gauges can have a design, shape, and feel that resemble gauges of a vehicle, like an automobile. The gauges can display relative values that simulate relative values found in a vehicle, like an automobile. The system can comprise a three tier computer architecture with a computer server, a back-end system, and a client computer. In one exemplary embodiment, the software can run on the client computer and then access certain graphical files for the gauges that can be stored on the computer server.Type: ApplicationFiled: July 26, 2006Publication date: January 31, 2008Applicant: LendingTree, LLCInventors: Tim Owens, Erick Mick, Jennifer Blamy
-
Patent number: D825328Type: GrantFiled: February 2, 2017Date of Patent: August 14, 2018Assignee: The Men's Wearhouse, Inc.Inventors: Doug Simpson, Rich Sullivan, Tim Owen